Drug Alert: CDSCO flags 64 drug samples including Aristo's Monocef 500
In its latest drug safety alert, the apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO) has flagged 62 medicine batches for failing to qualify for a random drug sample test for November– 2023, while two drug samples have been declared misbranded and spurious.
These drug samples which are declared not of standard quality include Meropenem Injection IP 0.5 g manufactured by Bharat Parenterals, Artesunate injection IP (Zynate) manufactured by Jackson Laboratories, Montelukast Sodium and Levocetirizine Hydrochloride Tablets I.P. manufactured by Unicure India, Ciprofloxacin tablets I.P. 500 mg manufactured by ANG Lifesciences India, Glimepiride tablets I.P. 1 mg manufactured by Apple Formulations and others.
For more details, check out the link given below:
CDSCO Drug Alert: 64 Drug Samples Including Aristo's Monocef 500 Flagged
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.